Granules India Ltd (GRANULES) — shareholding pattern, promoter holding, financials and share price

About Granules India Ltd (GRANULES)

Granules India Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as GRANULES and on the BSE under scrip code 532482. Its ISIN is INE101D01020.

Granules India Ltd and its subsidiaries are primarily involved in the manufacturing and selling of Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages. [1]

Granules India Limited is a vertically integrated pharmaceutical company specializing in Active Pharmaceutical Ingredient (API), Pharmaceutical Formulation Intermediates (PFI), and Finished Dosage (FD). Known for its leadership in off-patent drugs, it serves global branded and generic pharma firms with core products like Paracetamol and Ibuprofen.

In Q3 FY26, Granules India reported a 22% year-over-year revenue growth, driven mainly by the Finished Dosage segment in North America and Europe. Their EBITDA also saw a meaningful jump of 34% year-over-year, signifying improved operating leverage.

Listed peers in Pharmaceuticals: Rubicon Research Ltd, Piramal Pharma Ltd, Pfizer Ltd, Astrazeneca Pharma India Ltd, ERIS Lifesciences Ltd, Caplin Point Laboratories Ltd.

Valuation & Returns

10 Jul 2026

At ₹890 a share on 10 Jul 2026, Granules India Ltd (GRANULES) was valued at a price-to-earnings ratio of 37.06x against an industry P/E of 36.41x and a price-to-book of 5.94x on a book value of ₹149.94 per share as of Mar 2025. Solomo computes return on equity of 16.01% and return on capital employed of 17.39% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.

P/E
37.06x
Industry P/E
36.41x
P/B
5.94x
EPS (TTM)
₹24.01
Book value / share
₹149.94
ROE
16.01%
ROCE
17.39%
ROA
9.52%
Debt / equity
0.39x
Dividend yield
0.17%
EBITDA margin
22.39%
52-week range
₹433 – ₹901.1

Ratios are computed from filed results and the last recorded price. Not investment advice.

Financial Performance

Mar 2026

In the year ended Mar 2026, Granules India Ltd (GRANULES) reported revenue of ₹5,366 crore, net profit of ₹595 crore and earnings per share of ₹24.01. That compares with revenue of ₹4,482 crore and net profit of ₹502 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.

In the quarter ended Mar 2026, revenue was ₹1,471 crore and net profit ₹202 crore (consolidated).

Consolidated annual results for Granules India Ltd (GRANULES), Mar 2022 to Mar 2026. Revenue and net profit in ₹ crore; EPS in ₹ per share.
MetricMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue (₹ cr)3,7654,5124,5064,4825,366
Net profit (₹ cr)413517405502595
EPS (₹)16.6421.3416.7220.6824.01
Compound annual growth for Granules India Ltd (GRANULES). Stock price CAGR is price return and excludes dividends.
Measure10Y5Y3Y1Y
Sales growth9.37%5.58%-2.19%-0.55%
Profit growth11.41%-6.38%-6.17%23.74%
Stock price CAGR20%19%43%81%

Ownership Summary

Jun 2026

As of Jun 2026, promoters hold 38.02% of Granules India Ltd (GRANULES) (unchanged from the previous quarter), foreign institutional investors (FII) hold 17.5% and domestic institutional investors (DII) hold 16.11%. Market capitalisation was ₹22,054 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2002.

Largest disclosed public shareholders in Jun 2026: LIFE INSURANCE CORPORATION OF INDIA 4.1%, SBI LIFE INSURANCE CO. LTD 2.84%, KOTAK MAHINDRA LIFE INSURANCE COMPANY LTD. 1.7%, SMALLCAP WORLD FUND, INC 1.59%, ADITYA BIRLA SUN LIFE TRUSTEE PRIVATE LIMITED A/C 1.43%, BASAVA SANKARA RAO KOLLI 1.17%. Only stakes above the 1% disclosure threshold are named in filings.

QuarterPromoterPledgedFIIDIIPublic
Jun 202638.02%-17.5%16.11%61.98%
Mar 202638.02%-15.31%17.01%61.98%
Dec 202538.82%-13.55%17.48%61.18%
Sep 202538.82%-14.09%17.92%61.18%
Jun 202538.82%-13.24%23.53%61.18%
Mar 202538.84%-15.15%22.45%61.16%
Dec 202438.85%-15.87%19.57%61.15%
Sep 202438.87%-19.49%14.87%61.13%
Every quarter since Dec 2002 Filing data, not investment advice.